The Application of Evidence-Based Principles of Care in Older Persons (Issue 5): Alzheimer's Disease

Journal of the American Medical Directors Association

Volumn 8, Issue 3, 2007, Pages 183-193

  Zarowitz, Barbara J ^a,b   Stefanacci, Richard ^c   Hollenack, Kelly ^a   O'Shea, Terry ^a   Gruber, Joseph ^a   Tangalos, Eric G ^d  

^a Omnicare Inc   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c UNIVERSITY OF THE SCIENCES   (United States)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; ANTIOXIDANT; ANXIOLYTIC AGENT; BUSPIRONE; CARBAMAZEPINE; CHOLINESTERASE INHIBITOR; DONEPEZIL; ESTROGEN; GALANTAMINE; GINKGO BILOBA EXTRACT; HALOPERIDOL; LORAZEPAM; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; NORADRENALIN UPTAKE INHIBITOR; OLANZAPINE; PLACEBO; QUETIAPINE; RAZADYNE ER; RISPERIDONE; RIVASTIGMINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TACRINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROATE SEMISODIUM;

AGITATION; ALZHEIMER DISEASE; ANOREXIA; ARTICLE; BEHAVIOR DISORDER; CAREGIVER BURDEN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DIARRHEA; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG METABOLISM; ELDERLY CARE; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; FOOD; HEALTH CARE COST; HUMAN; INSTITUTIONAL CARE; LIVER TOXICITY; META ANALYSIS; NAUSEA AND VOMITING; QUALITY OF LIFE; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; URINE INCONTINENCE; VOMITING;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; EVIDENCE-BASED MEDICINE; GERIATRIC ASSESSMENT; HUMANS; INDANS; MENTAL DISORDERS; NOOTROPIC AGENTS; PHENYLCARBAMATES; PIPERIDINES; POSITRON-EMISSION TOMOGRAPHY; TACRINE;

EID: 33847338862     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2006.08.008     Document Type: Article

References (85)

1. Hebert L.E., Scherr P.A., Bienias J.L., et al. Alzheimer disease in the US population: Prevalence estimates using the 2000 census. Arch Neurol 60 8 (2003) 1119-1122
2. Evans D.A., Funkenstein H.H., Albert M.S., et al. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA 262 18 (1989) 2551-2556
3. US Department of Health and Human Services, National Institutes of Health. Progress report on Alzheimer's disease 2004-2005, November 2005. NIH Publication Number: 05-5724.
4. Leon J., Cheng C.K., and Neuman P.J. Alzheimer's disease care: Costs and potential savings. Health Affairs 17 6 (1998) 206-215
5. Ouslander J.G., and Weinberg A.D. Institutional long-term care services in the USA. In: Tallis R.C., and Fillit H.M. (Eds). Brocklehurst's Textbook of Geriatric Medicine and Gerontology. 6th ed. (2003), Elsevier/Churchill Livingstone, Barcelona, Spain
6. Koppel R. Alzheimer's Disease: The Costs to US Businesses in 2002 (2002), Alzheimer's Association, Washington, DC
7. Alzheimer's Disease Management Council (ADMC). Alzheimer's Disease: Risk Stratification, Patient Evaluation, and Outcome-Effective Pharmacologic Therapy. Year 2004 Clinical Update. Primary Care Consensus Reports (2004), Thomson American Health Consultants, Atlanta, GA 1-40
8. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Text Revision, DSM-IV TR. 4th ed. (2000), American Psychiatric Association, Washington, DC
9. Selkoe D.J. Amyloid protein and Alzheimer's disease. Sci Am 265 (1991) 68-78
10. Cummings J.L., Vinters H.V., Cole G.M., and Khachaturian Z.S. Alzheimer's disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities. Neurol 51 Suppl 1 (1998) S2-S17
11. American Medical Directors Association. Clinical Practice Guidelines: Dementia. Columbia, MD: The American Medical Directors Association. Available at: http://www.amda.com/tools/cpg/dementia.cfm. Accessed October 19, 2006.
12. Small G.W., Rabins P.V., Barry P.P., et al. Diagnosis and treatment of Alzheimer's disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association and the American Geriatrics Society. JAMA 278 (1977) 1363-1371
13. Richards S.S., and Hendrie H.C. Diagnosis, management, and treatment of Alzheimer's disease: A guide for the internist. Arch Intern Med 19 (1999) 789-798
14. Silverman D.H., Small G.W., Chang C.Y., et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA 286 (2001) 2120-2127
15. Keppler J.S., and Conti P.S. A cost analysis of positron emission tomography. AJR 177 (2001) 31-40
16. Desai A., and Grossberg G. Risk factors and protective factors for Alzheimer's disease. Clin Geriatr 7 (1999) 43-52
17. Filip V., and Kolibas E. Selegiline in the treatment of Alzheimer's disease: A long-term randomised placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group. J Psych Neurosci 24 (1999) 234-243
18. Alafuzoff I., Helisalmi S., Heinonen E.H., et al. Selegiline treatment and the extent of degenerative changes in brain tissue of patients with Alzheimer's disease. Eur J Clin Pharmacol 55 (2000) 815-819
19. Grundman M. Vitamin E and Alzheimer disease: The basis for additional clinical trials. Am J Clin Nutr 71 (2000) 630S-636S
20. Thomas T. Monoamine oxidase-B inhibitors in the treatment of Alzheimer's disease. Neurobiol Aging 21 (2000) 343-348
21. In t'Veld B.A., Ruitenberg A., Hofman A., et al. Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 345 (2001) 1515-1521
22. Peterson R.C., Thomas R.G., Grundman M., et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 352 (2005) 2379-2388
23. Moawad M.A. Possible relationship between statin use and decreased incidence of dementia: Are we ready for a new indication for these drugs?. Arch Intern Med 161 (2001) 1909-1910
24. Ernst E., and Pittler M.H. Ginkgo biloba for dementia. Clin Drug Invest 17 (1999) 301-308
25. Fillit H.M. The role of hormone replacement therapy in the prevention of Alzheimer's disease. Arch Intern Med 162 (2002) 1934-1942
26. Shumaker S.A., Legault C., Rapp S.T., et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in post-menopausal women. JAMA 289 (2003) 2651-2662
27. Mack J. Update and outlook in Alzheimer's disease. Drug Topics 140 (1996) 118-125
28. Doody R.S., Stevens J.C., Beck C., et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurol 56 (2001) 1154-1166
29. American Psychiatric Association. Practice guideline for the treatment of patients with Alzheimer's disease. Am J Psychiatry 154 (1997) 1-39
30. Hansen R.A., Gartlehner G., Kaufer D.J., et al., RTI-UNC Evidence-based Practice Center. Drug class review on Alzheimer's drugs (2005), Oregon Health and Science University, Portland, OR. http://www.ohsu.edu/drugeffectiveness/reports/final.cfm Available at: http://www.ohsu.edu/drugeffectiveness/reports/final.cfm. Accessed April 9, 2006.
31. Harris R.P., Helfand M., Woolf S.H., et al. Current methods of the US Preventative Services Task Force: A review of the process. Am J Prev Med 20 3Suppl (2001) 21-35
32. NHS Centre for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness: CRD's guidance for those carrying out or commissioning reviews. 2nd ed. (2001) York, UK: CRD Report Number 4
33. Wilcock G., Howe I., Coles H., et al. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging 20 (2003) 777-789
34. Jones R., Soininen H., Hager K., et al. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease. In J Geriatr Psychiatry 19 (2004) 58-67
35. Wilkinson D., Passmore A., Bullock R., et al. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. Int J Clin Pract 56 (2002) 441-446
36. Lanctot K., Herrmann N., Yau K., et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: A meta-analysis. CMAJ 169 (2003) 557-564
37. Birks J., and Wilcock G.G.W. Velnacrine for Alzheimer's disease. Cochrane Database Syst Rev 2 (2004) CD004748
38. Reisberg B., Doody R., Stoffler A., et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348 (2003) 1333-1341
39. Tariot P., Farlow M., Grossberg G., et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial. JAMA 291 (2004) 317-324
40. Schneider L. AD2000: Donepezil in Alzheimer's disease. Lancet 363 9427 (2004) 2100-2101
41. Erkinjuntti T., Kurz A., Gauthier S., et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 359 9314 (2002) 1283-1290
42. Kumar V., Anand R., Messina J., et al. An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. Eur J Neurol 7 (2000) 159-169
43. Areosa S.A., and Sherriff F. Memantine for dementia. Cochrane Database Syst Rev 3 (2005) CD003154
44. Emre M., Aarsland D., Albanese A., et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 351 (2004) 2509-2518
45. Blesa R., Davidson M., Kurz A., et al. Galantamine provides sustained benefits in patients with advanced moderate Alzheimer's disease for at least 12 months. Dement Geriatr Cogn Disorder 15 (2003) 79-87
46. Winblad B., Kilander L., Eriksson S., et al. Donepezil in patients with severe Alzheimer's disease: Double blind, parallel-group, placebo-controlled study. Lancet 367 (2006) 1057-1065
47. Holmes H.M., Hayley D.C., Alexander G.C., and Sachs G.A. Reconsidering medication appropriateness for patients late in life. Arch Intern Med 166 (2006) 605-609
48. Bogardus Jr. S.T. When should one stop cholinesterase inhibitors in patients with Alzheimer's disease?. J Psychiatry Neurosci 26 (2001) 425
49. Khang P., Weintraub N., and Espinoza R.T. The use, benefits, and costs of cholinesterase inhibitors for Alzheimer's dementia in long-term care: Are the data relevant and available?. J Am Med Dir Assoc 5 (2004) 249-255
50. Stefanacci R.G., and Cafiero A. Antidementia agents: What is important in this class?. J Clin Pharm Ther 30 (2005) 11-16
51. Messina J. Evaluation of the changes in concomitant psychotropic medications for patients with Alzheimer's disease treated with rivastigmine in a long-term care setting (2002) Paper presented at: Third International Meeting for the College of Psychiatric and Neurologic Pharmacists; April 16-19; Washington, DC
52. Suh D.C., Arcona S., Thomas S.K., et al. Risk of antipsychotic drug use in patients with Alzheimer's disease treated with rivastigmine. Drugs Aging 21 (2004) 395-403
53. Grossberg G.T., Corey-Bloom J., Small G.W., and Tariot P.N. Emerging therapeutic strategies for treating Alzheimer's disease in primary care. J Clin Psych 5 (2003) 268-277
54. Porsteinsson A.P., Tariot P.N., Erb R., et al. Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry 9 (2001) 58-66
55. Tariot P.N., Schneider L.S., Mintzer J.E., et al., Depakote Elderly Mania Study Group. Safety and tolerability of divalproex sodium for the treatment of signs and symptoms of mania in elderly patients with dementia: Results of a double-blind, placebo-controlled trial. Curr Ther Res 61 (2001) 51-67
56. Sival R.C., Haffmans P.M., Jansen P.A., et al. Sodium valproate in the treatment of aggressive behavior in patients with dementia-a randomized, placebo-controlled, clinical trial. Int J Geriatr Psych 17 (2002) 579-585
57. Cantillon M., Brunswick R., and Molina D. Buspirone vs haloperidol: A double-blind trial for agitation in a nursing home population with Alzheimer's disease. Am J Geriatr Psychiatry 4 (1996) 263-267
58. Tariot P.N., Erb R., Podgorski C.A., et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 155 (1998) 4-61
59. Sultzer D.L., Gray K.F., Gunay I., et al. A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. Am J Geriatr Psychiatry 5 (1997) 60-69
60. Teri L., Logsdon R.G., Peskind E., et al. Treatment of agitation in AD: A randomized, placebo-controlled clinical trial. Neurol 55 (2000) 1271-1278
61. Pollock B.G., Mulsant B.H., Rosen J., et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry 159 (2002) 460-465
62. Lanctot K.L., Hermann N., van Reekum R., et al. Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer's disease. Int J Geriatr Psychiatry 17 (2002) 531-541
63. Lyketsos C.G., DelCampo L., Steinberg M., et al. Treating depression in Alzheimer disease: Efficacy and safety of sertraline therapy, and the benefits of depression reduction: The DIADS. Arch Gen Psychiatry 60 (2003) 737-746
64. American Geriatrics Society and American Association for Geriatric Psychiatry. Consensus statement of improving the quality of mental health care in US nursing homes: Management of depression and behavioral symptoms associated with dementia. J Am Geriatr Soc 51 (2003) 1287-1298
65. Hemels M.E., Lanctot K.L., Iskedjian M., and Einarson T.R. Clinical and economic factors in the treatment of behavioral and psychological symptoms of dementia. Drugs Aging 18 (2001) 527-550
66. Katz I.R., Jeste D.V., Mintzer J.E., et al., Risperidone Study Group. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial. J Clin Psychiatry 60; (1999) 107-115
67. De Deyn P.P., Rabheru K., Rasmussen A., et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 53 (1999) 949-955
68. Brodaty H., Ames D., Snowdon J., et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation and psychosis of dementia. J Clin Psychiatry 64 (2003) 134-143
69. Street J.S., Clark W.S., Gannon K.S., et al., The HGEU Study Group. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer's disease in nursing care facilities: A double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 57 (2000) 968-976
70. De Deyn P.P., Carrasco M.M., Deberdt W., et al. Olanzapine vs placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. Int J Geriatr Psychiatry 19 (2004) 115-126
71. Meehan K.M., Wang H., David S.R., et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: A double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacol 26 (2002) 494-504
72. Fontaine C.S., Hynan L.S., Kock K., et al. A double-blind comparison of olanzapine vs risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities. J Clin Psychiatry 64 (2003) 726-730
73. Ballard C., Margallo-Lana M., Juszczak E., et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: Randomised double blind placebo controlled trial. BMJ 330 7496 (2005) 857-858
74. Behavioral Symptoms Associated with Dementia (2006), The Omnicare Geriatric Pharmaceutical Care Guidelines, Covington, KY 103-143 Anonymous
75. Carson S., McDonagh M.S., and Peterson K. A systematic review of the efficacy and safety of atypical antipsychotics in patients with psychological and behavioral symptoms of dementia. J Am Geriatr Soc 54 (2006) 354-361
76. Liperoti R., Gambassi G., Lapane K.L., et al. Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. J Clin Psychiatry 66 (2005) 1090-1096
77. Kuehn B.M. FDA warns antipsychotic drugs may be risky for elderly. JAMA 293 (2005) 2462
78. Bullock R. Treatment of behavioral and psychiatric symptoms in dementia: Implications of recent safety warnings. Curr Med Res Opin 21 (2005) 1-10
79. Schneider L.S., Dagerman K.S., and Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized placebo-controlled trials. JAMA 294 (2005) 1934-1943
80. Gill S.S., Rochon P.A., Herrmann N., et al. Atypical antipsychotic drugs and risk of ischaemic stroke: Population based retrospective cohort study. BMJ 330 7489 (2005) 445
81. Wang P.S., Schneeweiss S., Avorn J., et al. Risk of death in elderly users of conventional vs atypical antipsychotic medications. N Engl J Med 353 (2005) 2335-2341
82. Food and Drug Administration. April 2003 Safety Alert-Risperdal (risperidone). Available at http://www.fda.gov/medwatch/SAFETY/2003/risperdal.htm. Accessed April 19, 2006.
83. Food and Drug Administration. 2004 Safety Alert-Zyprexa (Olanzapine). Available at: http://www.fda.gov/medwatch/SAFETY/2004/safety04.htm#zyprexa. Accessed April 19, 2006.
84. Food and Drug Administration. 2004 Safety Alert-Risperdal (risperidone). Available at: http://www.fda.gov/medwatch/SAFETY/2004/safety04.htm#risperdal. Accessed April 19, 2006.
85. FDA Public Health Advisory. Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances. Available at: http://www.fda.gov/cder/drug/advisory/antipsychotics.htm. Accessed April 19, 2006.